Molecular and Cellular Biology, June 2007, p. 4207-4216, Vol. 27, No. 12
0270-7306/07/$08.00+0 doi:10.1128/MCB.00052-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Cell Biology, Lerner Research Institute and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic Foundation, Cleveland, Ohio 44195
Received 10 January 2007/ Returned for modification 14 February 2007/ Accepted 3 April 2007
|
|
|---|
)-induced E-selectin gene expression. In addition, HOXA9 specifically activated the E-selectin gene promoter in ECs. Progressive deletional analyses together with site-specific mutagenesis of the E-selectin promoter indicated that the Abd-B-like HOX DNA-binding motif, CAATTTTATTAA, located in the proximal region spanning bp 210 to 221 upstream of the transcription start site was crucial for the promoter induction by HOXA9. Both HOXA9 in EC nuclear extract and recombinant HOXA9 protein bound to this sequence in vitro. Moreover, we showed that HOXA9 binds temporally, in a TNF-
-dependent manner, to the region containing this Abd-B-like element in vivo. We have thus identified a novel and functionally critical cis-regulatory element for TNF-
-mediated transient expression of the E-selectin gene. Further, we provide evidence that HOXA9 acts as an obligate proinflammatory factor by mediating cytokine induction of E-selectin. |
|
|---|
), interleukin-1, lipopolysaccharides, and thrombin (4, 46, 47). In addition to taking part in the complex process of leukocyte recruitment (25), E-selectin also promotes metastasis by enhancing the adhesion of circulating tumor cells to the endothelium (28).
Promoter analysis studies have established the importance of the transcription factors NF-
B, ATF-2/Jun, and high-mobility-group protein I(Y) [HMG-I(Y)] in the transient induction of the E-selectin gene in EC (26, 34, 42). In addition, EC-specific histone modifications and chromatin remodeling at the E-selectin promoter have recently been implicated in the induction process (14). However, the kinetics of E-selectin gene expression reveal that even in the continuous presence of TNF-
, mRNA levels are transiently maintained for 8 h following transcriptional initiation, though NF-
B and ATF-2 proteins are still present in the nucleus at 24 h post-cytokine induction (6). Based on these observations, it is postulated that continuous stimulation of EC may lead to down-regulation and/or posttranslational modification of other transcriptional activators/coactivators necessary for the induction of the E-selectin gene.
Previous in vitro studies have implicated several members of the HOX gene cluster of homeobox transcription factors in the expression of cell adhesion molecules, such as E-cadherin in activated T cells, neural cell adhesion molecule, and liver cell adhesion molecule (19, 24, 33). However, little is known regarding the role of this gene family in the induction of EC-leukocyte adhesion molecules during EC activation. The highly homologous HOX genes are known to contribute significantly in specifying body plan and cell fate during development and in hematopoiesis (8, 9, 18, 21, 22, 30). They have also been reported to play a regulatory role in vascular cell differentiation and proliferation (3, 20). For example, studies have described the important contributions of HOX genes in establishing the angiogenic phenotype in EC (5, 39) and have identified HOXB5 as a potential transcriptional regulator of EC differentiation from mesoderm-derived precursor cells (54).
HOXA9, one of the Abd-B HOX family members, is required for normal development of the vertebral lumbar region and has also been implicated both in normal hematopoiesis and in leukemogenesis (17, 29, 32, 50, 52, 55). HOXA9 has been reported to function as a transcription factor, both alone and as a multiprotein complex with binding partner Pbx and/or Meis homeodomain protein (31, 41, 48). Moreover, posttranslational modification of HOXA9 protein by phosphorylation has been reported to modulate its DNA-binding activity and HOXA9-mediated gene transcription during myeloid differentiation (2, 51). HOXA9 expression levels are not only transcriptionally down-regulated in differentiated and mature hematopoietic cells (32, 44) but also posttranslationally down-regulated through a ubiquitin-dependent proteolytic mechanism (58). Recently, HOXA9 has been identified as a key regulator of endothelial commitment of adult progenitor cells (43). In addition, in previous studies, we have demonstrated a rapid down-regulation of the message level of one of the two splice variants (27) of the HOXA9 gene, HOXA9-EC/B in EC in response to stimulation with TNF-
, suggesting that HOXA9 is a potential regulator of EC homeostasis (41). HOXA9 has also recently been shown to exert its proangiogenic activity in EC by modulating the expression of EphB4 receptor tyrosine kinase (7, 13).
In the current study, we present evidence that HOXA9 in EC is required for the transcriptional induction of E-selectin by TNF-
, and this induction is mediated through the binding of HOXA9 to a specific Abd-B-like sequence, located at bp 210 to 221 from the transcription start site. These results are the first to reveal a proinflammatory role of HOXA9 in the induction of an "activation gene" in EC.
|
|
|---|
N70, HOXA9
N150, and HOXA9
N205, containing only the homeodomain and the short C-terminal tail of HOXA9. The constructs were checked for protein translation in vitro as described above. Reporter luciferase constructs containing a 510-bp fragment of the human E-selectin promoter 5' flanking region (E-510) and 400 bp of the human platelet-derived growth factor B (PDGF-B) chain promoter 5' flanking region (P-400) were generated by subcloning into the pGL3-Basic vector (Promega) as previously described (16, 45). The mutant promoter construct (E-510m) was created by mutating two bases at bp 219 to 216 (AATA to CAGA) to disrupt the HOXA9-binding core sequence at the Abd-B-like site by PCR and subcloning subsequently into the pGL3-Basic vector. The deletion promoter constructs were generated by suitable restriction enzyme digestions or by PCR followed by subcloning. The plasmid pCMVß (Clontech) containing the ß-galactosidase gene driven by the cytomegalovirus (CMV) promoter was used as a control in the transfection experiments. Details of vector construction and primer sequences are available upon request.
Cell culture and transfection.
Human umbilical vein EC were maintained in MCDB 107 medium supplemented with 15% fetal bovine serum, 150 µg/ml endothelial cell growth supplement, and 90 µg/ml heparin as previously described (45). Dulbecco modified Eagle medium containing 5% fetal bovine serum was used for the maintenance of bovine aortic EC. Lipofectin-mediated transfections (Life Technologies, Inc.) of effector, reporter, and control plasmids were carried out in cultured cells at 80 to 90% confluence with endotoxin-free DNA for 6 h using OptiMEM, and cells were allowed to recover in serum-containing media for 16 to 20 h before harvesting or TNF-
treatment. Luciferase activity was measured for reporter expression in triplicate and corrected for transfection efficiency by cotransfection with the plasmid vector pCMVß and measurement of the ß-galactosidase activity with the Galactolight Plus detection system (Tropix). All results were verified by multiple independent experiments using at least two different batches of endotoxin-free plasmid DNA.
Real-time PCR assay.
First-strand cDNA was synthesized from total RNA (1 µg), isolated from untreated EC or EC treated with TNF-
(2 ng/ml), in a 50-µl reaction mixture, using the SuperScript first-strand synthesis system for reverse transcription-PCR (Life Technologies) according to the manufacturer's instructions. Five microliters of this reaction mixture was used to perform PCR with specific primer pairs corresponding to a particular gene of interest. Real-time PCR was performed using SYBR green PCR core reagents (PE Applied Biosystems, United Kingdom) and a PerkinElmer ABI PRISM 7700 sequence detector according to the manufacturers instructions. Details of primer sequences are available upon request.
Western blot analysis. The level of protein expression, either endogenous or recombinant, was assessed by conventional immunoblotting. Both rabbit reticulocyte lysates and cell extracts from EC were separated on 10 to 12% SDS-PAGE gels by electrophoresis and then transferred to Immobilon-P membranes. The blots were incubated with protein-specific primary antibodies followed by horseradish peroxidase-conjugated specific secondary antibodies according to the manufacturer's instructions. Immunocomplexes were detected by enhanced chemiluminescence (Amersham Pharmacia Biotech). Anti-HOXA9 obtained from Upstate Biotechnology (Lake Placid, NY) and anti-E-selectin antibody obtained from Santa Cruz Biotechnology (Santa Cruz, CA) were used. Monoclonal anti-ß-actin and monoclonal antibody (M2) to the FLAG epitope were obtained from Sigma (St. Louis, MO).
RNA interference. Specific small interfering RNAs (siRNAs) for the HOXA9 target sequence (AACTACTACGTGGACTCGTTC) and scrambled sequence (AAGCCTCAGATAGTCTTCTCG) were designed and synthesized using a Silencer siRNA construction kit (Ambion).
Transfection experiments with siRNA were performed using Targefect F-2 and peptide enhancer (Targeting Systems, CA) according to the manufacturer's instructions with a minor modification. Targefect F-2 (5 µl/ml), peptide enhancer (5 µl/ml), and 50 nM siRNA were successively added to Dulbecco modified Eagle medium, thoroughly mixed, and kept at 37°C for 30 min. Human EC (>90% confluent) were incubated with the transfection mixture for 4 to 5 h. Cells were replenished with fresh EC culture medium and, following a 24-h incubation period, treated with TNF-
(2 ng/ml) for both 90 min and 3 h. Cells were harvested for subsequent RNA and protein analyses.
EMSA and UV cross-linking.
EMSA was performed with both nuclear extract (20 µg) and in vitro-translated protein as described previously (41) with the following modifications. Rabbit reticulocyte lysate (5 µl) expressing either FLAG-tagged HOXA9 protein or the control was used in a 25-µl final reaction volume in a buffer containing 20 mM HEPES (pH 7.5), 60 to 75 mM NaCl, 2 mM MgCl2, 1 mM dithiothreitol, 500 µg/ml bovine serum albumin, 5% glycerol, and 2.5 µg of poly(dI-dC). DNA probes labeled using T4 polymerase and [
-32P]ATP were subsequently incubated with this reaction mixture at room temperature for 20 min. DNA-protein complexes were resolved on a 6% polyacrylamide gel in 0.25% Tris-buffered saline buffer, followed by autoradiography or phosphorimaging analysis. For competition or supershift assays, the appropriate oligonucleotides or antibodies were used. The sequences of E-selectin promoter DNA probes used for the EMSA were as follows: Abd-B-like site forward, GTATATGCAATTTTATTAATAT, and Abd-B-like site reverse, ATATTAATAAAATTGCATATAC. UV cross-linking was performed as previously described (1). Nuclear extracts (20 µg) prepared from human EC were incubated with 32P-labeled double-stranded DNA (Abd-B-like site of E-selectin promoter) for 20 min at 4°C. The labeled covalent protein-DNA complexes were resolved on a 10% SDS gel by electrophoresis and detected by autoradiography.
ChIP assay.
The chromatin immunoprecipitation (ChIP) assay was performed using a kit (Upstate Biotechnology, NY) according to the manufacturer's instructions with some modifications. Human EC (5 x 106) were treated with TNF-
(2 ng/ml) for 1 h and 3 h. Both control untreated and TNF-
-treated cells were cross-linked by adding 1% formaldehyde directly to the culture medium for 10 min at 37°C. The cells were then lysed with the lysis buffer supplied in the kit and sonicated at 4°C for five 10-s periods with the setting at 3 (Branson Sonifier 450). Approximately 1% of the resulting sample was kept to serve as an input genomic DNA control, and the rest was precleared with salmon sperm DNA-protein A. Cell lysates were incubated with HOXA9 antibody (N-20; Santa Cruz Biotechnology) overnight at 4°C with rotation, followed by a 1-h incubation with protein A-agarose for ChIP. HOXA9 in the immunoprecipitate was detected by Western blotting. The precipitated chromatin-HOXA9 complex was washed and eluted, and cross-links were reversed by heating at 65°C for 4 h. The genomic DNA fragments, thus isolated, were purified by phenol-chloroform extraction and ethanol precipitation and amplified by PCR. The PCR products were separated on a 2% agarose gel. Three primer sets for PCR were designed to cover different regions of the E-selectin promoter. The product of the first set of primers spanned the sequence from bp 133 to +5 (138 bp) covering the HOXA9-binding site located in the TATA-box area in the E-selectin minimal promoter. The primer sequences were 5'-GCATCGTGGATATTCCCGGGAAAG-3' and 5'-CAGCTGAACACTACTTCGGCTGAGG-3'. The second product spanned the sequence from bp 326 to 110 (217 bp) covering the Abd-B-like site. The primer sequences were 5'-CTACCACAACTACATGAGAGACACTAC-3' and 5'-CTTTCCCGGGAATATCCACGATGC-3'. The third product spanned the sequence from bp 515 to 320 (195 bp), serving as a control. The primer sequences were 5'-ATCTACCTTGTGAGTCATTC-3' and 5'-TAGTTGTGGTAGTAATTAGAAT-3'. The primer sequences used for the PCR amplification of a region of the EphB4 promoter in ChIP analysis were described earlier (7).
Flow cytometric analysis.
Human EC were transiently cotransfected with pEGFPC-3 and a plasmid expressing either FLAG-HOXA9 or FLAG-Hoxa2, using Targefect F-2 (Targeting Systems) at a molar ratio of 1:2 according to the manufacturer's protocol with some modification. Transfections were carried out in triplicate in cultured 80 to 90% confluent EC with endotoxin-free DNA (0.5 µg/ml), using Targefect F-2 (5 µl/ml) and peptide enhancer (5 µl/ml) for 4 h. Cells were allowed to recover in serum-containing media for 16 to 20 h prior to treatment with TNF-
(2 ng/ml) for 1, 5, 15, or 30 h. EC were collected by centrifugation after being dislodged from the dish by using cell dissociation solution (Sigma). To detect the surface expression of E-selectin, cells were incubated with anti-human E-selectin (CD62E) monoclonal antibody (R&D Systems, MN) at a 1:100 dilution for 30 min at room temperature, washed, and subsequently incubated for 30 min with phycoerythrin-conjugated secondary antibody at a 1:200 dilution. Cells, either fresh or fixed with 2% paraformaldehyde, were analyzed by fluorescence-activated cell sorting (FACS; Becton Dickinson and Co., NJ) for the detection of both green fluorescent protein (GFP) and E-selectin protein.
Statistical analysis. Data from at least three independent experiments were analyzed and expressed as means ± standard deviations (SD). Statistical analysis was performed by Student's t test to compare two data sets and analysis of variance for serial analyses.
|
|
|---|
-induced expression of the EC-leukocyte adhesion molecule E-selectin.
In previous studies, we demonstrated that TNF-
regulated EC expression of the HOXA9 gene, suggesting a role for this transcription factor in modulating EC-specific genes during cytokine activation (41). One such gene is the leukocyte adhesion molecule E-selectin, which is transiently expressed on the surface of cytokine-activated EC. Direct analysis of the E-selectin promoter sequence revealed one highly conserved potential Abd-B HOX DNA-binding site consisting of the HOX consensus core element, the TTAT sequence. This site consists of a nearly identical inverted abdominal B (Abd-B) sequence (CAATTTTATTAA) from base pairs 210 to 221. The E-selectin promoter also contains a HOX DNA-binding consensus site (TTTACTGG) from base pairs 82 to 75 and an inverted HOX recognition sequence within the TATA-box region (TTTTATAGG) from base pairs 24 to 32 from the transcriptional start site.
We directly addressed the role of HOXA9 in the induction of E-selectin in TNF-
-treated EC by using HOXA9-specific siRNA to ablate HOXA9 protein levels. Transfection of EC with HOXA9 siRNA led to efficient suppression (>60%) of TNF-
-induced E-selectin mRNA expression compared to transfection of EC with scrambled siRNA (Fig. 1A). In contrast, the suppression of HOXA9 protein levels had no effect on TNF-
-induced intracellular adhesion molecule 1 (ICAM-1) expression in EC (Fig. 1A). Simultaneously, the TNF-
-induced E-selectin protein, which is absent in resting EC, was significantly reduced (
60%) in EC transfected specifically with HOXA9 siRNA (Fig. 1B). Multiple E-selectin protein bands with molecular masses of
115 kDa suggest the posttranslational modification of E-selectin, as has previously been reported (40, 56). The HOXA9 protein (
32 kDa) was constitutively expressed in EC, and a 3-h TNF-
treatment had little, if any, effect on the protein level. Most importantly, the results demonstrated that the siRNA was highly specific in attenuating HOXA9 protein levels in both control and TNF-
-treated EC (Fig. 1C). Although HOXA9 message was reduced in TNF-
-treated EC at 4 h, as reported previously (41), the steady-state level of HOXA9 protein was modestly changed, which is consistent with the HOXA9 half-life of >3 h as reported by others (58). These results thus demonstrate that HOXA9 protein is constitutively expressed in human EC and that it is required for TNF-
induction of the E-selectin gene.
![]() View larger version (32K): [in a new window] |
FIG. 1. HOXA9 regulates TNF- -induced expression of E-selectin. Human EC were transfected with HOXA9 siRNA or scrambled RNA for 24 h and treated with TNF- (2 ng/ml) for an additional 90 min or 3 h, respectively, as described in Materials and Methods. E-selectin or ICAM-1 mRNA, isolated from both untreated EC and EC treated with TNF- for 90 min, was measured by real-time PCR (A); the percent change was calculated relative to that of mock-transfected EC. Each mRNA expression level was normalized to that of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA expression. Data represent the means ± SD for three replicate experiments. *, P < 0.05 versus mock. E-selectin (B) or HOXA9 (C) protein levels were detected in EC whole-cell lysates of both untreated EC and EC treated with TNF- for 3 h by Western blot analysis. The blots were subsequently reprobed for ß-actin as an internal loading control. The protein levels were quantified by densitometry; the percent change was calculated relative to that of mock-transfected EC. Data represent the means ± SD for three replicate experiments. *, P < 0.05 versus mock (B); **, P < 0.01 versus mock untreated or versus mock TNF- -treated EC (C).
|
4-fold induction of E-selectin promoter activity. The expression of another HOX gene, Hoxa2, also in a CMV-driven promoter construct, had no influence on E-selectin promoter transactivation. In addition, HOXA9 overexpression failed to transactivate the P-400 PDGF-B chain promoter (Fig. 2A). Similar results were obtained using human EC (data not shown). The results in Fig. 2B demonstrate the relative expression levels of the transfected FLAG-tagged HOXA9 and Hoxa2 proteins in bovine EC and are consistent with the concentrations of transfected plasmids.
![]() View larger version (42K): [in a new window] |
FIG. 2. (A) E-selectin promoter activity is up-regulated by HOXA9. FLAG-HOXA9 or FLAG-Hoxa2 cDNA expression constructs in the pcDNA3 vector were cotransfected with the promoter-luciferase reporter construct (0.5 µg/ml) pGL3-E-510 (containing the fragment spanning bp 510 to +1 of the human E-selectin promoter) or pGL3-P-400 (containing the fragment spanning bp 400 to +1 of the human PDGF-B chain promoter) into bovine EC. The reporter luciferase activity was normalized by cotransfecting pCMV ß-galactosidase (20 ng/ml). Relative normalized luciferase activity is expressed as n-fold induction compared to that of control vector transfection. Data represent the means ± SD for three replicate experiments (*, P < 0.05 versus control; **, P < 0.01 versus control). (B) Western blot analyses of both FLAG-tagged Hoxa2 and HOXA9 protein levels in corresponding cDNA-transfected bovine EC. Cell lysates of transfected EC were analyzed for protein levels by SDS-PAGE and immunoblotting. A monoclonal anti-FLAG antibody was used for the immunodetection of both FLAG-tagged HOXA9 and Hoxa2. Each lane in the figure indicates the plasmid concentration used for transfection. Control lanes represent vector transfection.
|
-induced factors (37) in the induction of the E-selectin promoter. We cotransfected the E-selectin promoter reporter (E-510) with control (empty CMV vector), HOXA9, or Hoxa2 expression vectors in bovine EC and studied reporter activity following treatment with TNF-
. As shown in Fig. 3, TNF-
elicited an
8-fold induction of E-selectin promoter activity when either control or Hoxa2 expression vectors were cotransfected. As noted above, HOXA9 expression alone was sufficient to elicit an
4-fold induction in E-selectin promoter activity, and TNF-
treatment resulted in an additional increase in E-selectin promoter activity. These results, therefore, support our earlier observation and further implicate HOXA9 as a factor that participates positively with other TNF-
-induced factors in activating the E-selectin promoter.
![]() View larger version (22K): [in a new window] |
FIG. 3. HOXA9 coexpression augments TNF- activation of the E-selectin promoter. The pcDNA3-HOXA9 or Hoxa2 cDNA expression construct (1.5 µg/ml) was cotransfected into bovine EC with the pGL3-E-510 E-selectin promoter reporter construct (0.5 µg/ml). The reporter luciferase activity was normalized by cotransfecting pCMV ß-galactosidase (20 ng/ml). Relative normalized luciferase activity is expressed as n-fold induction compared to that of control vector transfection. Data represent the means ± SD for three replicate experiments (*, P < 0.05 versus TNF- -treated control or Hoxa2).
|
N70,
N150, and
N205, when expressed using an in vitro translation system, produce HOXA9 proteins with deletions representing 70, 150, and 205 amino acid residues, respectively, from the N terminus (data not shown). Cotransfection of the full-length HOXA9 expression plasmid with the E-selectin promoter-luciferase reporter resulted in the induction of the E-selectin promoter in bovine EC; however, cotransfection of the HOXA9 deletion constructs yielded little promoter activation (Fig. 4). Deletion of the first 70 amino acid residues from the N terminus resulted in nearly complete abrogation (
80%) of E-selectin promoter activation compared to full-length HOXA9. Further deletion of HOXA9,
N150 or
N205, consistently maintained this loss in transactivation. In addition, the expression of a heterologous chimeric construct in which the HOXA9 DNA-binding homeodomain was replaced with the GAL-4 DNA-binding domain was also completely ineffective in mediating E-selectin promoter transactivation (not shown). Taken together, these results demonstrate that the expression of a fully functional HOXA9 protein, containing both its DNA-binding and transactivation domains, is required for E-selectin promoter activation.
![]() View larger version (24K): [in a new window] |
FIG. 4. Both the transactivation and DNA-binding domains of HOXA9 are required for E-selectin promoter up-regulation. The pGL3-E-510 E-selectin promoter reporter construct (0.5 µg/ml) was cotransfected into bovine EC with control pcDNA3 vector, the full-length HOXA9 construct, or the HOXA9 N70, N150, or N205 deletion construct (1.5 µg/ml). The reporter luciferase activity was normalized by cotransfecting pCMV ß-galactosidase (20 ng/ml). Relative normalized luciferase activity is expressed as n-fold induction compared to that of control vector transfection. Data represent the means ± SD for three replicate experiments (*, P < 0.05 versus HOXA9; **, P < 0.01 versus HOXA9).
|
![]() View larger version (42K): [in a new window] |
FIG. 5. (A) In vitro translation of HOXA9. [35S]methionine-labeled HOXA9 was synthesized using a pcDNA3 construct in rabbit reticulocyte lysate with T7 polymerase in a coupled transcription-translation system (Promega). Autoradiogram of SDS-polyacrylamide gel showing the presence of an 32-kDa FLAG-tagged HOXA9 protein (lane 2) and control reaction products containing pcDNA3 vector only (lane 1). (B) Western blot analysis of in vitro-translated FLAG-tagged HOXA9. Rabbit reticulocyte lysates were analyzed for translation products by SDS-PAGE and immunoblotting. A monoclonal anti-FLAG antibody was used for the immunodetection of FLAG-tagged HOXA9. The vector lane represents the control reaction. (C) Specific binding of HOXA9 to the Abd-B-like site in the E-selectin promoter. An EMSA was performed by incubating in vitro-translated FLAG-tagged HOXA9 in rabbit reticulocyte lysate and a double-stranded 32P-labeled Abd-B-like site oligonucleotide, as described in Materials and Methods. Lane 1, no-lysate control; lane 2, control lysate; lane 3, lysate expressing FLAG-tagged HOXA9; lane 4, incubation with monoclonal anti-FLAG antibody; lane 5, incubation with mouse IgG.
|
25 to 35 kDa) and the 22-mer oligonucleotide (
15 kDa). The complexes were also specific for the Abd-B-like HOX consensus sequence, as revealed by competition with a 10-fold excess of the unlabeled wild-type oligonucleotide (Fig. 6, lane 3). One such complex appeared to be highly specific for HOXA9, since it was not affected by nonspecific IgG (Fig. 6, lane 4), but disappeared in the presence of HOXA9-specific antibody (Fig. 6, lane 5). These results suggest that both the endogenous and the in vitro-translated HOXA9 protein generate a highly specific protein-DNA complex with the Abd-B-like site of the E-selectin promoter. However, no HOXA9-specific protein-DNA complex was detected when either of the two other HOX-binding motifs, as described earlier, was used in this assay (data not shown).
![]() View larger version (52K): [in a new window] |
FIG. 6. HOXA9 present in EC nuclear extracts binds to the Abd-B-like site. Human EC nuclear extracts were incubated and UV cross-linked to a double-stranded 32P-labeled oligonucleotide (Oligo) containing the Abd-B-like site (GTATATGCAATTTTATTAATAT), as described in Materials and Methods. Reaction products were analyzed by 10% SDS-PAGE. Lane 1, binding reaction in the absence of UV treatment; lane 2, binding reaction following UV treatment; lane 3, binding reaction including a 10-fold molar excess of an unlabeled Abd-B-like site oligonucleotide; lane 4, binding reaction including normal rabbit IgG (2 µg); lane 5, binding reaction including rabbit polyclonal anti-HOXA9 antibody (2 µg).
|
when the ATF-2 site is deleted (construct at bp 143) and completely TNF-
-unresponsive upon deletion of the first NF-
B site (construct at bp 119). We performed transient cotransfection studies with HOXA9 and the various truncated promoter reporter constructs. As shown in Fig. 7, deletion to position 271 had little effect on HOXA9-induced E-selectin promoter transactivation. Further deletion of the 5' sequences to position 188, resulting in the elimination of the Abd-B-like site, led to a significant reduction (>60%) in HOXA9-mediated promoter induction. This result clearly demonstrates the critical role of the region spanning positions 271 to 188 containing the Abd-B-like site in HOXA9-induced E-selectin promoter transactivation. However, successive deletions to position 143, 117, 73, or 52 did not show any additional change in promoter induction. We were not able to observe a complete loss of HOXA9-mediated promoter induction. This may be due to the fact that the TATA-box region, still present in our 52 deletion construct, contains a consensus HOXA9-binding site.
![]() View larger version (15K): [in a new window] |
FIG. 7. The Abd-B-like site contributes to E-selectin promoter up-regulation by HOXA9. The indicated luciferase reporter constructs (0.5 µg/ml) were transiently cotransfected in triplicate into bovine EC with or without 1.5 µg/ml of a HOXA9 expression vector. The presence of defined response elements relative to the reporter constructs used is indicated on the left. The reporter luciferase activity was normalized by cotransfecting pCMV ß-galactosidase (20 ng/ml). Relative normalized luciferase activity is expressed as induction compared to that of control vector transfection.
|
6.5-fold induction of the E-selectin promoter (Fig. 8); however, mutation in the Abd-B-like site substantially abrogated promoter activation (>70% reduction compared to that of the wild-type promoter). This result, therefore, confirms a crucial role for the Abd-B-like site in the transactivation of the E-selectin promoter.
![]() View larger version (25K): [in a new window] |
FIG. 8. Mutation of the Abd-B-like site significantly reduces HOXA9-mediated induction of the E-selectin promoter. The pGL3-E-510 or pGL3-E-510m (mutated in the Abd-B-like site) E-selectin promoter reporter construct (0.5 µg/ml) was transiently cotransfected with either the pcDNA3 control or the HOXA9 expression construct (1.5 µg/ml) into bovine EC. The reporter luciferase activity was normalized by cotransfecting pCMV ß-galactosidase (20 ng/ml). Relative normalized luciferase activity is expressed as n-fold induction compared to that of control vector transfection. Data represent the means ± SD for three replicate experiments (*, P < 0.05 versus E-510/HOXA9).
|
. We, therefore, performed ChIP assays with a HOXA9-specific antibody by using cellular lysates from TNF-
-treated human EC. As shown in Fig. 9A (upper panel), with primers amplifying sequences spanning from positions 326 to 110 of the E-selectin promoter, which includes the Abd-B-like site, a 216-bp DNA fragment was amplified from anti-HOXA9 chromatin precipitates from 1-h TNF-
-treated cells. Anti-HOXA9 precipitates from untreated control or 3-h TNF-
-treated EC resulted in little or no DNA amplification. These results demonstrate that in EC, TNF-
induces the transient binding of HOXA9 to the Abd-B-like site. When the appropriate primers for the region spanning from positions 133 to +5, containing the two other consensus HOX DNA-binding sites, were used to amplify chromatin immunoprecipitated with anti-HOXA9, no DNA fragment was amplified from either control or TNF-
-treated EC (Fig. 9A, middle panel). These results confirm the data for HOXA9 DNA binding with the Abd-B-like site (Fig. 5C and 6). Finally, no DNA fragment was amplified from chromatin immunoprecipitated with anti-HOXA9 antibodies from either TNF-
-treated or untreated EC with primers amplifying the sequence from positions 515 to 320 (Fig. 9A, lower panel). With all three sets of primers, no DNA was amplified from chromatin immunoprecipitated with control IgG (data not shown). This transient, TNF-
-dependent interaction of HOXA9 with the E-selectin promoter differs from the case of another important EC gene, that for the EphB4 promoter (7), which constitutively bound HOXA9 independent of TNF-
(Fig. 9B).
![]() View larger version (32K): [in a new window] |
FIG. 9. HOXA9 binds transiently to the E-selectin promoter region containing the Abd-B-like site in response to TNF- . ChIP assays were performed, using anti-HOXA9-specific antibodies, with human EC treated in the absence or presence of TNF- for the indicated times. Three distinct sets of primers spanning different regions of the E-selectin promoter were used to amplify the immunoprecipitated (IP) DNA. (A) The upper panel represents amplified DNA, using primers spanning the E-selectin sequence from bp 326 to 110, containing the Abd-B-like site; the middle panel represents amplified DNA, using primers spanning the E-selectin sequence from bp 133 to +5, containing the TATA-box site; and the lower panel represents amplified DNA, using primers that span the E-selectin sequence from bp 515 to 320. The PCR products of both input and ChIP samples were loaded as indicated and analyzed using a 2% agarose gel. Data represent one of three similar sets of experiments. (B) The PCR products of both input and ChIP samples of the immunoprecipitated EphB4 promoter were loaded as indicated and analyzed using a 2% agarose gel. All the amplified immunoprecipitated DNA fragments were sequenced for identification following gel purification (data not shown).
|
-dependent transient expression pattern of the E-selectin gene.
Since we postulated that the down-regulation of HOXA9 may represent an "off switch" to attenuate E-selectin expression (41), we examined whether the overexpression of HOXA9 resulted in a sustained level of E-selectin protein on the EC surface. Both a GFP expression vector and either the HOXA9 or Hoxa2 construct were cotransfected into EC, and the surface expression of E-selectin protein was monitored by FACS analysis. As known previously, the majority of EC exhibited surface expression of E-selectin in response to TNF-
treatment for 5 h (Fig. 10A). Further, in spite of the continuous presence of TNF-
, E-selectin protein levels were reduced significantly at 15 h and essentially to basal levels at 30 h. However, the TNF-
-dependent transient surface expression profile of E-selectin remained unaltered in EC overexpressing both GFP and either HOXA9 or control Hoxa2. This was independently supported by Western blot analysis of E-selectin protein levels in total cell lysates of control as well as transfected EC (data not shown). Although the overexpressed protein levels were determined to be comparable (Fig. 10B), ChIP analysis failed to show HOXA9 binding to the Abd-B-like site beyond 1 h following TNF-
treatment as noted above (Fig. 10C). Thus, temporal binding of HOXA9 to the E-selectin gene promoter in spite of its persistent presence in EC appears to be important for E-selectin gene expression in EC, but continued overexpression does not negate the "turning off" of E-selectin expression at later times following TNF-
stimulation.
![]() View larger version (25K): [in a new window] |
FIG. 10. FACS analysis of E-selectin surface expression kinetics. Early-passage human EC were cotransfected for 24 h with the constructs expressing GFP and either HOXA9 or Hoxa2. Following treatment of both control and cotransfected cells with TNF- (2 ng/ml) for 0, 5, 15, or 30 h, cells were dislodged and assayed for E-selectin surface expression by FACS analysis using a human E-selectin-specific antibody, as described in Materials and Methods. Data were expressed as the percentage of the total EC population for the control and the percentage of GFP-positive EC for transfected cells expressing surface E-selectin (A). Results are the means for two individual experiments. Following 24 h of transfection, FLAG-HOXA9 or FLAG-Hoxa2 protein levels were detected by Western blot analysis of whole-cell lysates of both untreated and TNF- -treated EC for the indicated times (B). For the ChIP assay, primers spanning the E-selectin sequence from bp 326 to 110, containing the Abd-B-like site, were used for PCR amplification of both input and immunoprecipitated (IP) DNA as described in the legend to Fig. 9. The PCR products of both input and ChIP samples of the immunoprecipitated E-selectin promoter were loaded as indicated and analyzed using a 2% agarose gel (C).
|
|
|
|---|
B (10), a cyclic AMP-independent ATF family member, ATF-2 (26), and HMG-I(Y) (34). Recent results have suggested a model for EC-specific induction of the E-selectin gene in which multiple coactivators, including p300 and I
B kinase
, are required and the core promoter chromatin architecture is specifically remodeled in EC (14). In addition, other unidentified regulatory factors that may specify lineage-specific expression in the endothelium have also been proposed to play a role in the induction of the E-selectin gene. Here, we have identified for the first time a role for the TNF-
-modulated homeobox gene HOXA9, the expression of which is restricted principally to cells of endothelial and hematopoietic origin, in the regulated transcription of E-selectin. The active participation of HOXA9, an important regulator of organ development, in the induction of E-selectin is consistent with the finding that E-selectin is differentially regulated and expressed in endothelial lineage cells during development (36).
In this report, we have demonstrated that the depletion of HOXA9 by specific siRNA resulted in a significant inhibition of E-selectin protein expression in TNF-
-activated EC, though the induction of another important EC-leukocyte adhesion molecule, ICAM-1, was unaffected. It should be noted that while the E-selectin promoter contains multiple HOX-binding elements, ICAM-1 lacks these elements. The Abd-B-like HOX proteins, including HOXA9, recognize DNA-binding motifs with the core sequence TTTAT/C; however, HOXA9 has also been reported to bind motifs with a core TAAT in either inhibiting osteopontin expression in transforming growth factor ß-stimulated epithelial cells (49) or inducing EphB4 expression in EC (7). Moreover, in myeloid cells, HOXA9 activates the transcription of the CYBB gene by binding to the Hox/Pbx consensus-like element (ATGATTAT) together with Pbx1 (2). DNA-binding functional trimeric complexes containing HOXA9 and TALE proteins, Pbx and Meis, respectively, are present in leukemic cells and bind to consensus sequence A/GTGATTT/AAT/CG (48).
The physiological relevance of multiple HOX-binding elements within the E-selectin proximal promoter has not been explored previously. Here, we report on the existence of three motifs containing the core recognition sequence (TTTAT/C) for Abd-B-like HOX proteins within the E-selectin promoter at bp 210 to 221, 82 to 75, and 24 to 32. However, the Abd-B-like site at bp 210 is highly homologous with the Drosophila Abd-B consensus sequence (AAATTTTATG/TG/AC), whereas the other two sites have flanking nucleotides that do not resemble the consensus sequence. Our results from promoter deletion experiments demonstrate that neither the 82 site nor the 24 site has a significant impact on HOXA9-induced E-selectin promoter activity.
The Abd-B-like site, on the other hand, is functionally important in HOXA9-induced E-selectin promoter transactivation, as evidenced by both deletional analysis and site-directed mutagenesis. HOXA9 protein, either endogenous or recombinant, directly binds to the Abd-B-like site, as shown by in vitro protein-DNA interaction studies. In vivo ChIP assays have also identified specific and temporal HOXA9 binding to this Abd-B-like site in a TNF-
-dependent manner. Therefore, specific biologic processes must impart selectivity toward the Abd-B-like site among the three motifs in the E-selectin promoter. In addition, the lack of binding at later time points following TNF-
treatment is in contrast to the findings that HOXA9 constitutively interacts with the EC tyrosine kinase receptor EphB4 promoter (7) and remains associated in the continual presence of TNF-
. Both the TNF-
-induced E-selectin-specific "histone code" and posttranslational modification of HOXA9, as reported earlier (2, 14), may account for this difference. Future study is needed to elucidate the role, if any, of the other two sites in the induction of the E-selectin gene by other agonists, considering the presence of other Abd-B-like HOX proteins in EC.
Previous studies have indicated that the activation of two distinct but highly regulated parallel pathways involving both sequence-specific DNA binding and associations among transcription factors, including NF-
B, ATF-2/Jun, and HMG-I(Y), is required for the transcriptional induction of the E-selectin promoter (53). Such interactions have been proposed to be important for E-selectin promoter looping to bring those factors in close proximity to each other and/or for the transcription initiation site in controlling transcriptional activity (35, 37). It is possible that as a critical site-specific transcription factor, HOXA9 alters the spatial configuration of the promoter, resulting in activated transcription by binding to the Abd-B-like site in response to TNF-
. Alternatively, HOXA9 DNA binding may promote the stabilization of a multimeric transcriptional complex by bringing the Abd-B-like site close to the TATA box through promoter looping. However, we did not observe any physical association between HOXA9 and the transcription initiation factor TF-IID (data not shown), though such interaction could be highly transient in nature. Moreover, HOXA9, in addition to binding DNA, may associate with the crucial architectural factor HMG-I(Y), which has been proposed to be a general cofactor in HOX-mediated transcriptional activation (57). We are currently investigating such a possibility in the E-selectin induction process.
Finally, results based on our current study as well as previous studies (41) suggest a possible explanation for the active down-regulation of E-selectin gene induction following TNF-
treatment. We propose that both the spatial and temporal chromatin binding and subsequent down-regulation of HOXA9, not alone but concomitantly with other functionally critical factors, including the chromatin modifying factor SWI/SNF, as reported earlier (14), may constitute the "off-switch" circuitry for the E-selectin gene. Further supporting evidence comes from our finding using FACS analysis that even sustained overexpression of HOXA9 alone, in conformity with its temporal chromatin binding only in the presence of TNF-
, did not increase the persistence of E-selectin on the EC surface.
In summary, we have demonstrated that HOXA9 is involved in the transcriptional up-regulation of the E-selectin gene in EC by binding to a specific Abd-B-like sequence in the E-selectin promoter. Moreover, our results suggest that the binding of HOXA9 to this Abd-B-like site in the E-selectin promoter is temporally mediated by TNF-
. These results, therefore, identify a specific role for HOXA9 in EC activation in which it acts as a potential proinflammatory factor in the induction of EC-leukocyte adhesion molecules, such as E-selectin.
We thank E. Poptic, P. Hoang, and L. Mavrakis for cell culture assistance. Human umbilical vein endothelial cells were isolated from the cords collected by the Cleveland Clinic Birthing Services and the Perinatal Clinical Research Center (supported by National Institutes of Health Research Center award RR-00080) at the Cleveland MetroHealth Hospital.
Published ahead of print on 23 April 2007. ![]()
|
|
|---|
B and function in the activation of the E-selectin promoter in response to cytokines. Mol. Cell. Biol. 13:7180-7190.
B complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine-induced expression of the E-selectin promoter. Mol. Cell. Biol. 14:5701-5709.This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»